Clinical Updates on the Treament of Elderly Patients with Hodgkin Lymphoma

Adcetris® in the BrECADD regimen is recommended as a standard treatment option for very fit patients aged 61–75 years with newly diagnosed classical Hodgkin lymphoma (cHL) in advanced stages. [1] The recommendation is based on the favorable results from the phase 2 ad-on cohort analysis of the HD21 phase 3 study*, comparing BrECADD vs. eBEACOPP as first line treatment in older patients aged 61-75 years with advanced CD30+ cHL. [2] PD Dr. med. Paul J Bröckelmann, member of the German Hodgkin Study Group (GHSG), provides further insights on this topic.
 

Image

* Phase II, prospective, international, multicenter, single-arm supplemental cohort within the HD21-study for patients with cHL aged >60 years (N=85, age: 61–75 years). [2]


BrECADD: brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone; cHL: classical Hodgkin lymphoma; eBEACOPP: escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone


Healthcare professionals may request a complete copy of the cited literature from the pharmaceutical company.


Adcetris® Information for healthcare professionals, www.swissmedicinfo-pro.ch

C-APROM/CH/ADCE/0101 11/2025

Further information

References

  • 1. Eyre TA, et al. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2025:S0923-7534(25)00911-1.

  • 2. Ferdinandus J, et al. Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With AdvancedStage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial. J Clin Oncol 2025;43(27):2974–2985.